A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes

Incretin-based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors have gained prominence in recent years for the treatment of type 2 diabetes (T2D). Such therapies offer the potential to stimulate endogenous insulin activity in prop...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Saudi Med J
Autors principals: Alshali, Khalid Z., Karawagh, Abdullah M.
Format: Artigo
Idioma:Inglês
Publicat: Saudi Medical Journal 2016
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5018698/
https://ncbi.nlm.nih.gov/pubmed/27464858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15537/smj.2016.8.15800
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars